Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841655 | 0.80 | TSHR (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL18402915 | 0.78 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL13248046 | 0.78 | POLB (0.49) | MEN1KMT2AALDH1A1TDP1TSHR | |
| SCHEMBL3032856 | 0.78 | CYP1A2 (0.57) | MEN1KMT2AALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL22664416 | 0.76 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1TDP1TSHR | |
| SCHEMBL9607638 | 0.74 | POLB (0.49) | MEN1KMT2AALDH1A1TDP1TSHR | |
| SCHEMBL29954598 | 0.74 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2TDP1TSHRLMNA | |
| SCHEMBL10966874 | 0.74 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2TDP1TSHRLMNA | |
| SCHEMBL11335572 | 0.73 | GABRA1 (0.54) | ALDH1A1SMN1; SMN2TSHRLMNAHTT | |
| SCHEMBL17449717 | 0.73 | HSD17B10 (0.55) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269738-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | MEN1 1793/4885KMT2A 4470/4885ALDH1A1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.